藥明合聯(02268.HK)預計11月17日上市 Invesco等豪華基石陣容加持
格隆匯11月7日丨藥明合聯(02268.HK)發佈公吿，公司擬全球發售約1.78億股股份，中國香港發售股份1784.5萬股，國際發售股份約1.61億股；2023年11月7日至11月10日招股，預期定價日為11月10日；發售價將為每股發售股份19.90-20.60港元，每手買賣單位500股；Morgan Stanley、Goldman Sachs及J.P. Morgan為聯席保薦人；預期股份將於2023年11月17日於聯交所主板掛牌上市。
公司是專注於全球抗體藥物偶聯物(“ADC”)及更廣泛生物偶聯藥物市場的領先合同研究、開發及製造組織(“CRDMO”)，亦是一家致力於提供全面綜合服務的公司。憑藉在生物藥和小分子藥物方面的專業知識，公司提供跨學科綜合服務，涵蓋生物偶聯藥物的發現、研究、開發及製造。公司設立位置鄰近的專用實驗室及生產基地提供該等服務，從而可能大幅縮短開發時間及成本。根據弗若斯特沙利文的資料，按2022年的收益計，公司是全球第二大ADC等生物偶聯藥物CRDMO。公司按收益計的全球市場份額由2020年的1.8%上升至2021年的4.6%，並進一步上升至2022年的9.8%。
公司已訂立基石投資協議，據此，基石投資者已同意在遵守若干情況下按發售價認購，或促使彼等的指定實體按發售價認購合共約23.466億港元可認購的有關數目發售股份。假設超額配股權未獲行使，緊隨全球發售完成後：按發售價每股發售股份20.25港元(即本招股章程所載指示性發售價範圍的中位數)計算，基石投資者將予認購的發售股份總數將為約1.16億股發售股份。基石投資者包括Invesco Advisers, Inc.、General Atlantic Singapore SPV 64 Pte. Ltd.、Al-Rayyan Holding LLC、UBS Asset Management (Singapore) Ltd.、HongShan Funds、Novo Holdings A/S、以及Lake Bleu Funds。
假設發售價為每股股份20.25港元(即指示性發售價範圍每股股份19.90港元至20.60港元的中位數)，在超額配股權未獲行使的情況下，公司估計全球發售所得款項淨額將約為34.23億港元。公司目前擬將全球發售所得款項淨額約67%用於在新加坡興建公司的設施及擴大公司在中國的服務實力及能力，以進一步擴大公司的服務實力及能力；所得款項淨額的約23%將用於有選擇地尋求戰略聯盟、投資及收購機會，主要旨在擴大公司的技術平台及服務類型和能力；以及所得款項淨額的約10%用作營運資金及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
